REFERENCES

1. Speicher MR, Carter NE 'The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet 2005;6:782-92.

2. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybrid­ization to microarrays.

3. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005;437:376-80.

4. Fogel BL, Lee H, Strom SP, Deignan JL, Nelson SF. Clinical exome sequencing in neurogenetic and neuropsychiatric disorders. Ann N Ã Acad Sci 2015;1366:49-60.

5. Shendure J, Porreca GJ, Reppas NB, et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005;309:1728-32.

6. Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single- gene, gene panel, or exome/ genome sequencing. Genet Med 2015;17:444-51.

7. Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med 2015;7:80.

8. Cooper DN, Chen JM, Ball EV, et al. Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. Hum Mutat 2010;31:631-55.

9. Benko S, Fantes JA, Amiel J, et al. Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin se­quence. Nat Genet 2009;41:359-64.

10. Lettice LA, Heaney SJ, Purdie LA, et al. A long- range Shh enhancer regulates expression in the developing limb and fin and is associ­ated with preaxial polydactyly. Hum Mol Genet 2003;12:1725-35.

11. Mirkovic N, Marti-Renom MA, Weber BL, Sali A, Monteiro AN. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predispos­ition. Cancer Res 2004;64:3790-97.

12. Ferrer-Costa C, Orozco M, de la Cruz X.

13. Kanai K, Yoshida S, Hirose S, et al. Physicochemical property changes of amino acid residues that accompany missense muta­tions in SCN1A affect epilepsy phenotype severity. J Med Genet 2009;46:671-79.

14. Hofstra RM, Spurdle AB, Eccles D, et al. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clin­ical significance. Hum Mutat 2008;29:1292-303.

15. Inbar-Feigenberg M, Choufani S, Butcher DT, Roifman M, Weksberg R. Basic concepts of epigenetics. Fertil Steril 2013;99:607-15.

16. Cedar H, Bergman Y. Linking DNA methylation and histone modi­fication: patterns and paradigms. Nat Rev Genet 2009;10:295-304.

17. Lande-Diner L, Zhang J, Ben-Porath I, et al. Role of DNA methy­lation in stable gene repression. J Biol Chem 2007;282:12194-200.

18. Gardner KE, Allis CD, Strahl BD. Operating on chromatin, a col­orful language where context matters. J Mol Biol 2011;409:36-46.

19. Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 2011;90:430-40.

20. Barton SC, Surani MA, Norris ML. Role of paternal and maternal genomes in mouse development. Nature 1984;311:374-76.

21. McGrath J, Solter D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 1984;37:179-83.

22. Ishida M, Moore GE. The role of imprinted genes in humans. Mol Aspects Med 2013;34:826-40.

23. Moore GE, Ishida M, Demetriou C, et al. The role and interaction of imprinted genes in human fetal growth. Philos Trans R Soc Lond B Biol Sci 2015;370:20140074.

24. Demetriou C, Abu-Amero S, Thomas AC. Paternally expressed, imprinted insulin-like growth factor-2 in chorionic villi correlates significantly with birth weight. PLoS One 2014;9:e85454.

25. Gicquel C, Gaston V, Mandelbaum J, Siffroi JP, Flahault A, Le Bouc Y.

26. Hoeijmakers L, Kempe H, Verschure PJ. Epigenetic imprinting during assisted reproductive technologies: the effect of temporal and cumulative fluctuations in methionine cycling on the DNA methylation state. Mol Reprod Dev 2016;83:94-107.

27. Uyar A, Seli E. The impact of assisted reproductive technologies on genomic imprinting and imprinting disorders. Curr Opin Obstet Gynecol 2014;26:210-21.

28. Doornbos ME, Maas SM, McDonnell J, Vermeiden JP, Hennekam RC. Infertility, assisted reproduction technologies and imprinting disturbances: a Dutch study. Hum Reprod 2007;22:2476-80.

29. Houshdaran S, Cortessis VK, Siegmund K, Yang A, Laird PW, Sokol RZ. Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm. PLoS One 2007;2:e1289.

30. Bickmore WA. Karyotype analysis and chromosome banding. In: Encyclopedia of Life Sciences, pp. 1-7. London: Nature Publishing Group; 2001.

31. Francke U. Digitized and differentially shaded human chromo­some ideograms for genomic applications. Cytogenet Cell Genet 1994;65:206-18.

32. Pinkel D, Gray JW, Trask B, van den Engh G, Fuscoe J, van Dekken H. Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. Cold Spring Harb Symp Quant Biol 1986;51:151-57.

33. Moore JW, Binder GA, Berry R. Prenatal diagnosis of aneuploidy and deletion 22q11.2 in fetuses with ultrasound detection of car­diac defects. Am J Obstet Gynecol 2004;191:2068-73.

34. Goldmuntz E, Clark BJ, Mitchell LE. Frequency of 22q11 dele­tions in patients with conotruncal defects. J Am Coll Cardiol 1998;32:492-98.

35. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybrid­ization to microarrays. Nat Genet 1998;20:207-11.

36. Pollack JR, Perou CM, Alizadeh AA, et al.

37. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-46.

38. Ahn JW, Bint S, Bergbaum A, Mann K, Hall RP, Ogilvie CM. Array CGH as a first line diagnostic test in place of karyotyping for post­natal referrals—results from four years’ clinical application for over 8,700 patients. Mol Cytogenet 2013;6:16.

39. Miller DT, Adam MP, Aradhya S, et al. Consensus state­ment: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749-64.

40. Park SJ, Jung EH, Ryu RS, Kang HW, et al. Clinical implementa­tion of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases. Mol Cytogenet 2011;4:12.

41. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain­terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-67.

42. Lee LG, Connell CR, Woo SL, et al. DNA sequencing with dye- labeled terminators and T7 DNA polymerase: effect of dyes and dNTPs on incorporation of dye-terminators and probability ana­lysis oftermination fragments. Nucleic Acids Res 1992;20:2471-83.

43. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.

44. Aarskog NK, Vedeler CA. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in heredi­tary neuropathy with liability to pressure palsies. Hum Genet 2000;107:494-98.

45. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population.

46. Campbell PJ, Stephens PJ, Pleasance ED, et al. Identification of somatically acquired rearrangements in cancer using genome­wide massively parallel paired-end sequencing. Nat Genet 2008;40:722-29.

47. Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet 2010;11:31-46.

48. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on gen­omics. Cell 2013;155:27-38.

49. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011;12: 745-55.

50. Gilissen C, Hoischen A, Brunner HG, Veltman JA. Disease gene identification strategies for exome sequencing. Eur J Hum Genet 2012;20:490-97.

51. Trottier Y, Biancalana V, Mandel JL. Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. JMed Genet 1994;31:377-82.

52. Tsai PY, Chang CH, Yu CH, Cheng YC, Chang FM. Three­dimensional ultrasound in the prenatal diagnosis of osteogenesis imperfecta. Taiwan J Obstet Gynecol 2012;51:387-92.

53. Thompson EM. Non-invasive prenatal diagnosis of osteogenesis imperfecta. Am JMed Genet 1993;45:201-206

54. Gusman M, Servaes S, Feygin T, Degenhardt K, Epelman M. Multimodal imaging in the prenatal diagnosis of tuberous scler­osis complex. Case Rep Pediatr 2012;2012:925646.

55. Harper PS. Practical Genetic Counselling. Boca Raton, FL: CRC Press; 2010.

56. Young ID. Introduction to Risk Calculation in Genetic Counselling. New York: Oxford University Press; 2007.

57. Yates JR, van Bakel I, Sepp T, et al. Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum Mol Genet 1997;6:2265-69.

58. Bittles A. Consanguinity and its relevance to clinical genetics. Clin Genet 2001;60:89-98.

59. Massie J, Ioannou L, Delatycki M. Prenatal and preconception population carrier screening for cystic fibrosis in Australia: where are we up to? AustN Z J Obstet Gynaecol 2014;54:503-509.

60. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-thalassaemia: a review of international prac­tice. Eur J Hum Genet 2010;18:1077-83.

61. Rai R, Regan L. Recurrent miscarriage. Lancet 2006;368:601-11.

62. Hogge WA, Byrnes AL, Lanasa MC, Surti U. The clinical use of karyotyping spontaneous abortions. Am J Obstet Gynecol 2003;189:397-400.

63. De Braekeleer M, Dao TN. Cytogenetic studies in couples experi­encing repeated pregnancy losses. Hum Reprod 1990;5:519-28.

64. Goddijn M, Joosten JH, Knegt AC, et al. Clinical relevance of diagnosing structural chromosome abnormalities in couples with repeated miscarriage. Hum Reprod 2004;19:1013-17.

65. Munne S, Morrison L, Fung J, et al. Spontaneous abortions are reduced after preconception diagnosis of translocations. J Assist Reprod Genet 1998;15:290-96.

66. Munne S, Sandalinas M, Escudero T, Fung J, Gianaroli L, Cohen J. Outcome of preimplantation genetic diagnosis of translocations. J Fertil Steril 2000;73:1209-18.

67. Scriven PN, Flinter FA, Braude PR, Ogilvie CM. Robertsonian translocations-reproductive risks and indications for preimplan­tation genetic diagnosis. Hum Reprod 2001;16:2267-73.

68. Midro AT, Stengel-Rutkowski S, Stene J. Experiences with risk estimates for carriers of chromosomal reciprocal translocations. Clin Genet 1992;41:113-22.

69. Barisic I, Zergollern L, Muzinic D, Hitrec V Risk estimates for balanced reciprocal translocation carriers—prenatal diagnosis experience. Clin Genet 1996;49:145-51.

70. Witmer JM, Wedl L, Black BJ. Genetic counseling: ethical and professional role implications. Couns Dev 1986;64:337-40.

71. Kessler S. Psychological aspects of genetic counseling. XIV Nondirectiveness and counseling skills. Genet Test 2001;5:187-91.

72. Hardy K, Martin KL, Leese HJ, Winston RM, Handyside AH. Human preimplantation development in vitro is not adversely af­fected by biopsy at the 8-cell stage. Hum Reprod 1990;5:708-14.

73. Harper JC, Sengupta SB. Preimplantation genetic diagnosis: state of the art 2011. Hum Genet 2012;131:175-86.

74. Hanson C, Jakobsson AH, Sjogren A, et al. Preimplantation gen­etic diagnosis (PGD): the Gothenburg experience. Acta Obstet Gynecol Scand 2001;80:331-36.

75. Fridstrom M, Ahrlund-Richter L, Iwarsson, et al. Clinical out­come of treatment cycles using preimplantation genetic diag­nosis for structural chromosomal abnormalities. Prenat Diagn 2001;21:781-87.

76. Mackie Ogilvie C, Scriven PN. Meiotic outcomes in reciprocal translocation carriers ascertained in 3-day human embryos. Eur J Hum Genet 2002;10:801-806.

77. Harton GL, De Rycke M, Fiorentino F, et al. ESHRE PGD consor­tium best practice guidelines for amplification-based PGD. Hum Reprod 2011;26:33-40.

78. Verlinsky Y, Cieslak J, Freidine M, et al. Pregnancies following pre-conception diagnosis of common aneuploidies by fluorescent in-situ hybridization. Hum Reprod 1995;10:1923-27.

79. Silber S, Escudero T, Lenahan K, Abdelhadi I, Kilani Z, Munne S. Chromosomal abnormalities in embryos derived from testicular sperm extraction. Fertil Steril 2003;79:30-38.

80. Wilding M, Forman R, Hogewind G, et al. Preimplantation genetic diagnosis for the treatment of failed in vitro fertilization-embryo transfer and habitual abortion. Fertil Steril 2004;81:1302-307.

81. Platteau P, Staessen C, Michiels A, Van Steirteghem A, Liebaers I, Devroey P. Preimplantation genetic diagnosis for aneuploidy screening in patients with unexplained recurrent miscarriages. Fertil Steril 2005;83:393-97.

82. Chen CK, Yu HT, Soong YK, Lee CL. New perspectives on pre­implantation genetic diagnosis and preimplantation genetic screening. Taiwan J Obstet Gynecol 2014;53:146-50.

83. van Echten-Arends J, Mastenbroek S, Sikkema-Raddatz B, et al. Chromosomal mosaicism in human preimplantation embryos: a systematic review. Hum Reprod Update 2011;17:620-27.

84. Mastenbroek S, Twisk M, van Echten-Arends JN. In vitro fer­tilization with preimplantation genetic screening. N Engl J Med 2007;357:9-17.

85. Yang Z, Liu J, Collins GS, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. Mol Cytogenet 2012;5:24.

86. Wells D, Kaur K, Grifo J, et al. Clinical utilisation of a rapid low- pass whole genome sequencing technique for the diagnosis of an- euploidy in human embryos prior to implantation. J Med Genet 2014;51:553-62.

87. Tabor A, Alfirevic Z. Update on procedure-related risks for pre­natal diagnosis techniques. Fetal Diagn Ther 2010;27:1-7.

88. Society for Maternal-Fetal Medicine (SMFM), Berry SM, Stone J, Norton ME, Johnson D, Berghella V Fetal blood sampling. Am J Obstet Gynecol 2013;209:170-80.

89. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-87

90. Lo YM. Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem 2000;46:1903-906.

91. Rijnders RJ, Van Der Luijt RB, Peters ED, et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 2003;23:1042-44.

92. Hyett JA, Gardener G, Stojilkovic-Mikic T, et al. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. Prenat Diagn 2005;25:1111-16.

93. Guibert J, Benachi A, Grebille AG, Ernault P, Zorn JR, Costa JM. Kinetics of SRY gene appearance in maternal serum: detection by real time PCR in early pregnancy after assisted reproductive tech­nique. Hum Reprod 2003;18:1733-36.

94. Honda H, Miharu N, Ohashi Y, et al. Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum. Hum Genet 2002;110:75-79.

95. Elejalde BR, de Elejalde MM, Heitman T. Visualization of the fetal genitalia by ultrasonography: a review of the literature and ana­lysis of its accuracy and ethical implications. J Ultrasound Med 1985;4:633-39.

96. Efrat Z, Akinfenwa OO, Nicolaides KH. First-trimester determin­ation of fetal gender by ultrasound. Ultrasound Obstet Gynecol 1999;13:305-307.

97. Chi C, Hyett JA, Finning KM, Lee CA, Kadir RA. Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia. BJOG 2006;113:239-42.

98. Chitty LS, Griffin DR, Meaney C, et al. New aids for the non- invasive prenatal diagnosis of achondroplasia: dysmorphic fea­tures, charts of fetal size and molecular confirmation using cell- free fetal DNA in maternal plasma. Ultrasound Obstet Gynecol 2011;37:283-89.

99. Chitty LS, Khalil A, Barrett AN, Pajkrt E, Griffin DR, Cole TJ. Safe, accurate, prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA. PrenatDiagn 2013;33:416-23.

100. Bustamante-Aragones A, Gallego-Merlo J, Trujillo-Tiebas MJ, et al. New strategy for the prenatal detection/exclusion of pa­ternal cystic fibrosis mutations in maternal plasma. J Cyst Fibros 2008;7:505-10.

101. Nasis O, Thompson S, Hong T, et al. Improvement in sensitivity of allele-specific PCR facilitates reliable noninvasive prenatal de­tection of cystic fibrosis. Clin Chem 2004;50:694-701.

102. Chitty LS, Mason S, Barrett AN, et al. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next­generation sequencing allows for a safer, more accurate, and comprehensive approach. Prenat Diagn 2015;35:656-62.

103. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. PrenatDiagn 2011;31:7-15.

104. Weremowicz S, Sandstrom DJ, Morton CC, Niedzwiecki CA, Sandstrom MM, Bieber FR. Fluorescence in situ hybridization (FISH) for rapid detection of aneuploidy: experience in 911 pre­natal cases. PrenatDiagn 2001;21:262-69.

105. Klinger K, Landes G, Shook D, et al. Rapid detection of chromosome aneuploidies in uncultured amniocytes by using fluorescence in situ hybridization (FISH). Am J Hum Genet 1992;51:55-65.

106. Pertl B, Pieber D, Lercher-Hartlieb A, et al. Rapid prenatal diag­nosis of aneuploidy by quantitative fluorescent PCR on fetal sam­ples from mothers at high risk for chromosome disorders. Mol Hum Reprod 1999;5:1176-79.

107. Mansfield ES. Diagnosis of Down syndrome and other aneuploidies using quantitative polymerase chain reaction and small tandem repeat polymorphisms. Hum Mol Genet 1993;2:43-50.

108. Leung WC, Lao TT. Rapid aneuploidy testing, traditional karyo­typing, or both? Lancet 2005;366:97-98.

109. Caine A, Maltby AE, Parkin CA, Waters JJ, Crolla JA; UK Association of Clinical Cytogeneticists (ACC). Prenatal detec­tion of Down’s syndrome by rapid aneuploidy testing for chromo­somes 13, 18, and 21 by FISH or PCR without a full karyotype: a cytogenetic risk assessment. Lancet 2005;366:123-28.

110. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015;45:249-66.

111. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on non- invasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395-98.

112. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372:1589-97.

113. Warsof SL, Larion S, Abuhamad AZ. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn 2015;35:972-79.

114. Minear MA, Lewis C, Pradhan S, Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenat Diagn 2015;35:959-67.

115. Kleeman L, Bianchi DW, Shaffer LG, et al. Use of array compara­tive genomic hybridization for prenatal diagnosis of fetuses with sonographic anomalies and normal metaphase karyotype. Prenat Diagn 2009;29:1213-17.

116. Van den Veyver IB, Patel A, Shaw CA, et al. Clinical use of array comparative genomic hybridization (aCGH) for prenatal diag­nosis in 300 cases. Prenat Diagn 2009;29:29-39.

117. Le Caignec C, Boceno M, Saugier-Veber P, et al. Detection of genomic imbalances by array based comparative genomic hy­bridisation in fetuses with multiple malformations. J Med Genet 2005;42:121-28.

118. Tyreman M, Abbott KM, Willatt LR, et al. High resolution array analysis: diagnosing pregnancies with abnormal ultrasound find­ings. J Med Genet 2009;46:531-41.

119. Van den Veyver IB, Beaudet AL. Comparative genomic hy­bridization and prenatal diagnosis. Curr Opin Obstet Gynecol 2006;18:185-91.

120. D’Amours G, Kibar Z, Mathonnet G, et al. Whole-genome array CGH identifies pathogenic copy number variations in fetuses with major malformations and a normal karyotype. Clin Genet 2012;81:128-41.

121. Evangelidou P, Alexandrou A, Moutafi M, et al. Implementation of high resolution whole genome array CGH in the prenatal clin­ical setting: advantages, challenges, and review of the literature. Biomed Res Int 2013;2013:346762.

122. Beggs AD, Hodgson SV Genomics and breast cancer: the different levels of inherited susceptibility. EurJHum Genet2009;17:855-56.

123. Volgelstein B, Kinzler KW The Genetic Basis of Human Cancer. London: McGraw-Hill; 2002.

124. Turnbull C, Hodgson S. Genetic predisposition to cancer. Clin Med (Lond) 2005;5:491-98.

125. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-41.

126. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 2009;17:722-31.

127. Knudson AG. Mutation and cancer: statistical study of retino­blastoma. Proc Natl. Acad Sci U S A 1971;68:820-23.

128. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.

129. Scully R. Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Res 2000;2:324-30.

130. Sowter HM, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005;26:1651-56.

131. Hopper JL, Southey MC, Dite GS, et al. Population-based esti­mate of the average age-specific cumulative risk of breast cancer for a defined set of protein-t runcating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-47.

132. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl CancerInst 2002;94:1358-65.

133. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:2918-21.

134. Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012;107:2005-2009.

135. Boland CR. Recent discoveries in the molecular genetics of Lynch syndrome. Fam Cancer 2016;15:395-403.

136. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009;76:1-18.

137. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with her­editary non-polyposis colon cancer. Nature 1994;368:258-61.

138. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994;263:1625-29.

139. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137:1621-27.

140. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime inci­dence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75:141-49.

141. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444-49.

142. Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralat­eral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2011;104:1384-92.

143. van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010;124:643-51.

144. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associ­ated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 2010;28:2404-10.

145. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27:5887-92.

146. Angelos P, Bedrosian I, Euhus DM, Herrmann VM, Katz SJ, Pusic A. Contralateral prophylactic mastectomy: challenging consid­erations for the surgeon. Ann Surg Oncol 2015;22:3208-12.

147. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: com­parison of breast conservation and mastectomy. Breast Cancer Res Treat 2010;121:389-98.

148. Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J 2011;17:492-99.

149. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduc­tion of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation car­riers. Br J Cancer 2005;93:287-92.

150. Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl) 2012;8:543-55.

151. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bi­lateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-79.

152. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mu­tation. N Engl J Med 2002;346:1609-15.

153. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo- oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-87.

154. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812-23.

155. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-69.

156. Wevers MR, Ausems MG, Verhoef S, et al. Behavioral and psy­chosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter ran­domized clinical trial. BMC Cancer 2011; 11:6.

157. Graves KD, Vegella P, Poggi EA, et al. Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomarkers Prev 2012;21:445-55.

158. Braithwaite D, Emery J, Walter F, Prevost AT, Sutton

S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. Fam Cancer 2006;5:61-75.

159. Hesse-Biber S, An C. Genetic testing and post-testing decision making among BRCA-positive mutation women: a psychosocial approach. J Genet Couns 2016;25:978-92.

160. Cheon JY, Mozersky J, Cook-Deegan R. Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come? Genome Med 2014;6:121.

161. Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol 2013;24 Suppl 8:viii69-74.

162. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-11.

163. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveil­lance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010;138:2300-306.

164. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012;107:24-30.

165. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-79.

166. Donnelly LS, Watson M, Moynihan C, et al. Reproductive deci­sion-making in young female carriers of a BRCA mutation. Hum Reprod 2013;28:1006-12.

167. Ormondroyd E, Donnelly L, Moynihan C, et al. Attitudes to re­productive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. Eur J Hum Genet 2012;20:4-10.

168. Lane M, Ngueng Feze I, Joly Y. Genetics and personal insur­ance: the perspectives of Canadian cancer genetic counselors. J Genet Couns 2015;24:1022-36.

169. Joly Y, Ngueng Feze I, Simard J. Genetic discrimination and life in­surance: a systematic review of the evidence. BMC Med 2013; 11:25.

170. Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: util­izing DNA repair deficiency as therapeutic target. Fam Cancer 2016;15:359-66.

171. Ricks TK, Chiu HJ, Ison G, et al. Successes and challenges of PARP inhibitors in cancer therapy. Front Oncol 2015;5:222.

172. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-17.

173. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.

174. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair de­fect in BRCA mutant cells in the design of new therapeutic strat­egies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-48.